HIV Treatment 2019

 

 

HIV_Treatment_Strategies_2019_Banner_720px

HIV_Tx19_LAUNCH_button

About the Program:


Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Back to Top

Program Objectives:

Upon completion of the program, participants should be able to:

  • Utilize current and emerging HIV therapies and treatment paradigms to improve their treatment of HIV-positive patients
  • Evaluate and apply criteria for evaluating current and emerging HIV therapies and treatment paradigms
  • Assess and discuss the latest data on HIV therapies and treatment paradigms
  • Compare and contrast major ARV guidelines recommendations with emerging HIV therapies and treatment paradigms and discuss the relative advantages and disadvantages
  • Discuss future directions in HIV treatment and research

Release Date: July 25, 2019

Expiration Date: July 25, 2020

Estimated time to complete each Module: 45 minutes per module

Media: Web

Back to Top

Faculty:

Eric Daar, MD (Co-Director)
Interim Chair, Department of Medicine
Chief, Division of HIV Medicine Harbor-UCLA Medical Center
Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, CA

Joseph Eron, MD (Co-Director)
Professor of Medicine, School of Medicine Chief
Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

W. David Hardy, MD
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Washington, DC

Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Pablo Tebas, MD
Professor of Medicine Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Back to Top

Accreditation Statement:

ACCME Commendation This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and ViralEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians

Back to Top

Credit Designation:

Module 1 (Choosing ART to Optimize Patient Outcomes):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 2 (Recent Data on HIV Therapies and Treatment Paradigms):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 3 (ART Choices when Guideline Recommendations Differ or are Incomplete): 
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 4 (Future Direction in HIV Treatment and Research):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

 

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

 

Eric Daar, MD

•Consulting Fees: Gilead

•Grant Support: Gilead, Merck, ViiV

 

Joseph Eron, MD

•Consulting Fees: Gilead, ViiV, Janssen, Merck

•Contracted Research: Gilead, ViiV, Janssen 

 

W. David Hardy, MD

•Advisory Board: Gilead, Merck, ViiV, CSL-Behring (Calimmune), Enochian

•Research Support: Gilead, Janssen, Merck ViiV 

  

Helena Kwakwa, MD

•Nothing to Disclose

 

Renslow Sherer, MD

•Nothing to Disclose

 

Pablo Tebas, MD

•Consulting Fees: Merck, Gilead, ViiV

•Royalty: UpToDate

 

University of Chicago Center for Continuing Medical Education and ViralEd, Inc Declarations

The staff of the Center for Continuing Medical Education and Viral Ed Inc. have no financial relationships to disclose.
Back to Top

Disclaimer:

 

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

 

Copyright © 2020 University of Chicago. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from The University of Chicago Center for Continuing Medical Education.

 

Back to Top

Computer System Requirements:

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player. 

Back to Top

·

U of Chicago

 

For CME Accreditation Questions, please click HERE

VE logo 300px 

This activity is supported by an independent educational grant from ViiV Healthcare.


  Jointly provided by the University of Chicago Pritzker School of Medicine and ViralEd, Inc.


ViralEd, LLC

http://www.viraled.com/modules/info/hiv_treatment_2019.html